décembre
Laurent FRENZEL Rev Francoph Hémost Thromb 2020 ; 2 (13) : A17. Konkle BA, Shapiro AD, Quon DV, Staber JM, Kulkarni R, Ragni MV, et al. BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. N Engl J Med 2020 ; 383 : 1018-27.
Michels A, Dwyer CN, Mewburn J, Nesbitt K, Kawecki C, Lenting P, et al. Arterioscler Thromb Vasc Biol 2020 ; 40 : 2860-74.
Fanny LASSALLE Rev Francoph Hémost Thromb 2020 ; 2 (12) : A16. Hillarp A, Strandberg K, Gustafsson KM, Lindahl T. Unveiling the complex effects of direct anticoagulants on dilute Russell’s viper venom time assays. J Thromb Haemost 2020 ; 18 : 1866-73.
novembre
Rosen S, Tiefenbacher S, Robinson M, Huang M, Srimani J, Mackenzie D, et al. Blood 2020 ; 136 : 2524-34.
Ragni M. Blood 2020 ; 136 : 2483-4.
Fanny LASSALLE Rev Francoph Hémost Thromb 2020 ; 2 (11) : A15. Chhabra ES, Liu T, Kulman J, Patarroyo-White S, Yang B, Lu Q, et al. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice. Blood 2020 ; 135 : 1484-96.
Jérôme ROLLIN Rev Francoph Hémost Thromb 2020 ; 2 (11) : A14. Cines DB, Zaitsev S, Rauova L, Rux AH, Stepanova V, Krishnaswamy S, et al. FcRn augments induction of tissue factor activity by IgG-containing immune complexes. Blood 2020 ; 135 : 2085-93.
octobre
Mehic D, Hofer S, Jungbauer C, Kaider A, Haslacher H, Eigenbauer E, et al. Blood Adv 2020 ; 4 : 5157-64.
Cuesta-Barriuso R, Gómez-Conesa A, López-Pina JA. Haemophilia 2020
Fanny LASSALLE Rev Francoph Hémost Thromb 2020 ; 2 (10) : A13. Roose E, Schelpe AS, Tellier E, Sinkovits G, Joly B, Dekimpe C, et al. Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura. Blood 2020 ; 13 : 353-61.
Smahi M, De Pooter N, Hollestelle MJ, Toulon P. J Thromb Haemost 2020;18:2613–2621.
Schulman S, El-Darzi E, Florido MH, Friesen M, Merrill-Skoloff G, Brake MA, et al. J Clin Invest 2020 ; 130 : 5302-12.
septembre
Giangrande P, Abdul Karim F, Nemes L, You CW, Landorph A, Geybels MS, et al. J Thromb Haemost 2020 ; 18 : 5-14.
Annabelle DUPONT Rev Francoph Hémost Thromb 2020 ; 2 (9) : A12. Pasi KJ, Rangarajan S, Mitchell N, Lester W, Symington E, Madan B, et al. N Engl J Med 2020 ; 382 : 29-40.
Konkle BA, Shapiro AD, Quon DV, Staber JM, Kulkarni R, Ragni MV, et al. BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. N Engl J Med 2020 ; 383 : 1018-27.
Zhang S, Liu Y, Wang X, Yang L, Li H, Wang Y, et al. J Hematol Oncol 2020 ; 13 : 120.
Sébastien LOBET, relecture par Dr Catherine LAMBERT Rev Francoph Hémost Thromb 2020 ; 2 (8) : A11. Peltier SJ, Mazepa MA, Freese RL, Nelson SF, Kearney SL, Reding MT. Opioid exposure in haemophilia patients is common and underreported. Haemophilia 2020 ; 26 : 251-6.
août
Hillarp A, Strandberg K, Gustafsson KM, Lindahl TL. J Thromb Haemost 2020 ; 18 : 1866-73.
juillet
Holstein K, Liu X, Smith A, Knöbl P, Klamroth R, Geisen U, et al. Blood 2020 ; 136 : 279-87.
Roose E, Schelpe AS, Tellier E, Sinkovits G, Joly BS, Dekimpe C, et al. Blood 2020 ; 136 : 353-61.
Annabelle DUPONT Rev Francoph Hémost Thromb 2020 ; 2 (7) : A10. Agnelli G, Becattini C, Meyer G, Munoz A, Huisman MV, Connors JM, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020 ; 382 : 1599-607.
juin
Tarrant J, Cormier M, Nesbitt K, Dwyer C, Hough C, Lillicrap D. Blood Adv 2020 ; 4 : 2644-55.
Fanny LASSALLE Rev Francoph Hémost Thromb 2020 ; 2 (6) : A9. Pishko A, Lefler D, Gimotty P, Paydary K, Fardin S, Arepally G, et al. The risk of major bleeding in patients with suspected heparin-induced thrombocytopenia. J Thromb Haemost 2019 ; 17 : 1956-65.
Cines DB, Zaitsev S, Rauova L, Rux AH, Stepanova V, Krishnaswamy S, et al. Blood 2020 ; 135 : 2085-93.
mai
Hanni C, Petrovitch E, Ali M, Gibson W, Giuliano C, Holzhausen J, et al. Blood Adv 2020 ; 4 : 2366-71.
Spyropoulos AC, Levy JH, Ageno W, Connors JM, Hunt BJ, Iba T, et al ; Subcommittee on Perioperative, Critical Care Thrombosis, Haemostasis of the Scientific, Standardization Committee of the International Society on Thrombosis, Haemostasis+. Thromb Haemost 2020. Epub ahead of print.
Ignas DM, Doria AS, von Drygalski A, Blanchette VS, Chang EY, Dover S, et al. Haemophilia 2020. Online ahead of print.
Jérôme ROLLIN Rev Francoph Hémost Thromb 2020 ; 2 (5) : A8. Sui J, Cao W, Halkidis K, Abdelgawwad MS, Kocher NK, Guillory B, et al. Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura. Blood Adv 2019 ; 3 : 4177-86.
Fanny LASSALLE Rev Francoph Hémost Thromb 2020 ; 2 (5) : A7. Atiq F, Schütte LM, Looijen AEM, Boender J, Cnossen MH, Eikenboom J, et al. von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD. Blood Adv 2019 ; 3 : 4147-54.
Gaudio A, Xourafa A, Rapisarda R, Zanoli L, Signorelli SS, Castellino P. Int J Mol Sci 2020 ; 21 : E3538.
Lenting PJ. Blood Adv 2020 ; 4 : 2111-8.
Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al ; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). Intensive Care Med 2020. Epub ahead of print.
avril
Laurent FRENZEL Rev Francoph Hémost Thromb 2020 ; 2 (4) : A6. Chaturvedi S, Braunstein EM, Yuan X, Yu J, Alexander A, Chen H, et al. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood 2020 ; 135 : 239-51.
Rapport final de l’étude de l’andexanet alfa dans les saignements associés aux inhibiteurs du facteur Xa
Annabelle DUPONT Rev Francoph Hémost Thromb 2020 ; 2 (4) : A5. Bhatt DL, Pollack CV, Weitz JI, Jennings LK, Xu S, Arnold SE, et al. Antibody-based Ticagrelor reversal agent in healthy volunteers. N Engl J Med 2019 ; 380 : 1825-33. Connoly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, et […]
mars
Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, et al ; Caravaggio Investigators. N Engl J Med 2020 ; 382 : 1599-1607.
Annabelle DUPONT Rev Francoph Hémost Thromb 2020 ; 2 (3) : A4. Shao Y, Wu W, Xu G, Wang X, Ding Q. Low factor V level ameliorates bleeding diathesis in patients with combined deficiency of factor V and factor VIIIl. Blood 2019 ; 134 : 1745-54.
Laurent FRENZEL Rev Francoph Hémost Thromb 2020 ; 2 (3) : A3. Levy GG, Asikanius E, Kuebler P, Benchikh El Fegoun S, Esbjerg S, Seremetis S. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program. J Thromb Haemost 2019 ; 17 : 1470-7.
février
Peltier SJ, Mazepa MA, Freese RL, Nelson SF, Kearney SL, Reding MT. Haemophilia 2020 ; 26 : 251‐6.
Darzi AJ, Karam SG, Charide R, Etxeandia-Ikobaltzeta I, Cushman M, Gould MK, et al. Blood 2020 ; 135 : 1788-810.
Seth Chhabra E, Liu T, Kulman J, Patarroyo-White S, Yang B, Lu Q, et al. Blood 2020 ; 135 : 1484-96.
Johnston I, Sarkar A, Hayes V, Koma GT, Arepally GM, Chen J, et al. Blood 2020 ; 135 : 1270-80.
Annabelle DUPONT Rev Francoph Hémost Thromb 2020 ; 2 (2) : A2. Male C, Lensing AWA, Palumbo JS, Kumar R, Nurmeev I, Hege K, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol 2020 ; 7 : e18-e27.
janvier
Fanny LASSALLE Rev Francoph Hémost Thromb 2020 ; 2 (1) : A1. Doshi BS, Rogers RS, Whitworth HB, Stabnick EA, Britton J, Butler RB, et al. Utility of repeat testing in the evaluation for von Willebrand disease in pediatric patients. J Thromb Haemost 2019 ; 17 : 1838-47.
Pasi KJ, Rangarajan S, Mitchell N, Lester W, Symington E, Madan B, et al. N Engl J Med 2020 ; 382 : 29-40.
